|
Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301). |
|
|
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Incyte (Inst); Incyte (Inst); Merck; Taiho Oncology (Inst) |
Research Funding - Bayer (Inst); G1 Therapeutics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst) |
|
|
Stock and Other Ownership Interests - Natera |
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Novartis |
Research Funding - AstraZeneca; Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Treos Bio |
Patents, Royalties, Other Intellectual Property - Treos Bio |
|
|
|
Stock and Other Ownership Interests - Treos Bio |
Patents, Royalties, Other Intellectual Property - Treos Bio |
|
|
|
Stock and Other Ownership Interests - Treos Bio |
Patents, Royalties, Other Intellectual Property - Treos Bio |
|
|
|
Patents, Royalties, Other Intellectual Property - Treos Bio |
|
|
No Relationships to Disclose |
|
|
|
Leadership - Treos Bio; Treos Bio |
Stock and Other Ownership Interests - Treos Bio |
Patents, Royalties, Other Intellectual Property - Treos Bio |